Results 171 to 180 of about 5,698,960 (306)

Ana Liffey Drug Project annual report 1993

, 1994
I note that the Project commenced in 1982 and since that time the range and level of services has been developed significantly. The Project was established at a time when the need for services for people with HIV/AIDS had not become apparent and it ...
Ana Liffey Drug Project
core  

ERK autoinhibition mechanism informs a drug combination strategy. [PDF]

Protein Sci
Regev C, Jang H, Nussinov R.
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

DeepSynBa: actionable drug combination prediction with complete dose-response profiles. [PDF]

Bioinformatics
Kuru HI, Zhang H, Rattray M, Ek CH, Cicek AE, Tastan O, Milo M.   +6 more
europepmc   +1 more source

Drug interactions and lethal drug combinations [PDF]

Journal of Clinical Pathology, 1975
openaire   +3 more sources

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Rethinking the role of synergy calculations in the next century of drug combination discovery. [PDF]

Med
Meyer CT, Dai Y, Pomeroy AE, Twarog NR, Bender A, Rosenfeld SS, Antonarakis ES, Mettetal JT, Huang RS, Quaranta V, Tang J, Shelat AA, Smith MA, Palmer AC.   +13 more
europepmc   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

Molecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic, Rafael Stroggilos, Mladen Marinkovic, Ana Djuric, Suzana Stojanovic‐Rundic, Radmila Jankovic, Sergi Castellvi‐Bel, Remond J.A. Fijneman, Antonia Vlahou, Jerome Zoidakis, Milena Cavic   +10 more
wiley   +1 more source

Overcoming Trypanosoma cruzi persistence with a mechanistically distinct drug combination. [PDF]

NPJ Antimicrob Resist
Francisco AF, Olmo F, Escudié F, Chatelain E, Kelly JM.   +4 more
europepmc   +1 more source